Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV
September 16, 2021 07:30 ET | Exavir Therapeutics
With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...
Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral
June 08, 2021 07:00 ET | Exavir Therapeutics
With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...
gmi 2018.png
Antidiabetics Market will surge at 10.6% CAGR from 2018 to 2024: Global Market Insights, Inc.
November 09, 2018 03:00 ET | Global Market Insights, Inc
Sellbyville, Delaware, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Global Antidiabetics Market will surpass USD 110 billion by 2024; according to a new research report by Global Market Insights, Inc....
gmi logo.jpg
Antidiabetics Market to surpass $110 Billion by 2024: Global Market Insights, Inc.
September 21, 2017 06:00 ET | Global Market Insights, Inc
Ocean View, Delaware, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Antidiabetics Market is poised to reach USD 110 billion by 2024; according to a new research report by Global Market Insights, Inc....